ArticleJournal of neurovirology2006
Dopaminergic marker proteins in the substantia nigra of human immunodeficiency virus type 1-infected brains.
Article in Journal of neurovirology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 33 citations in OpenAlex.
- Is There such a Thing as Post-Viral Depression?: Implications for Precision Medicine.Biomolecules & therapeutics · 2024Review
- Neurofunctional characteristics of executive control in older people with HIV infection: a comparison with Parkinson's disease.Brain imaging and behavior · 2022Article
- HIV-Associated Apathy/Depression and Neurocognitive Impairments Reflect Persistent Dopamine Deficits.Cells · 2021Review
- Chronic SSRI treatment reverses HIV-1 protein-mediated synaptodendritic damage.Journal of neurovirology · 2021Article
- Cognitive and motor deficits in older adults with HIV infection: Comparison with normal ageing and Parkinson's disease.Journal of neuropsychology · 2021Article
- Binding Mode of Human Norepinephrine Transporter Interacting with HIV-1 Tat.ACS chemical neuroscience · 2021Article
- HIV Infection and Neurocognitive Disorders in the Context of Chronic Drug Abuse: Evidence for Divergent Findings Dependent upon Prior Drug History.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Review
- Potential pharmacological approaches for the treatment of HIV-1 associated neurocognitive disorders.Fluids and barriers of the CNS · 2020Review
- Age-Related Decrease in Tyrosine Hydroxylase Immunoreactivity in the Substantia Nigra and Region-Specific Changes in Microglia Morphology in HIV-1 Tg Rats.Neurotoxicity research · 2019Article
- Selective monoaminergic and histaminergic circuit dysregulation following long-term HIV-1 protein exposure.Journal of neurovirology · 2019Article
- HIV-1 proteins dysregulate motivational processes and dopamine circuitry.Scientific reports · 2018Article
- HIV, Tat and dopamine transmission.Neurobiology of disease · 2017Review
- Role of Histidine 547 of Human Dopamine Transporter in Molecular Interaction with HIV-1 Tat and Dopamine Uptake.Scientific reports · 2016Article
- HIV Subtypes B and C gp120 and Methamphetamine Interaction: Dopaminergic System Implicates Differential Neuronal Toxicity.Scientific reports · 2015Article
- Molecular mechanism of HIV-1 Tat interacting with human dopamine transporter.ACS chemical neuroscience · 2015Article
- CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120.PloS one · 2013Article
- Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge.Current HIV research · 2012Article
- Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2012Article
- Immunomodulatory properties of kappa opioids and synthetic cannabinoids in HIV-1 neuropathogenesis.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2011Review
- Hyperdopaminergic tone in HIV-1 protein treated rats and cocaine sensitization.Journal of neurochemistry · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
With the advent of highly active antiretroviral therapy, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) is becoming a more chronic, manageable disease; nevertheless, the prevalence of neurological complications of AIDS is increasing. In this study, protein levels of tyrosine hydroxylase (TH) and dopamine transporter (DAT) in the substantia nigra of HIV-infected brains and -seronegative controls were determined by immunoblotting. The immunoreactivity of neuronal specific enolase (NSE) was used to assess cell loss. Although there were no changes in levels of immunoreactive DAT or NSE proteins in HIV brains, levels of immunoreactive TH were significantly reduced, relative to controls. These results suggest that decreases in TH, the rate-limiting enzyme of dopamine synthesis, may be a factor in the neurological manifestations of HIV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.